RU99118176A - METHOD FOR STABILIZING PEPTIDE AND CONTAINING PEPTIDE LYOPHYLIZED PHARMACEUTICAL COMPOSITION OBTAINED BY USING THIS METHOD - Google Patents
METHOD FOR STABILIZING PEPTIDE AND CONTAINING PEPTIDE LYOPHYLIZED PHARMACEUTICAL COMPOSITION OBTAINED BY USING THIS METHODInfo
- Publication number
- RU99118176A RU99118176A RU99118176/14A RU99118176A RU99118176A RU 99118176 A RU99118176 A RU 99118176A RU 99118176/14 A RU99118176/14 A RU 99118176/14A RU 99118176 A RU99118176 A RU 99118176A RU 99118176 A RU99118176 A RU 99118176A
- Authority
- RU
- Russia
- Prior art keywords
- hirudin
- organic acid
- peptide
- pharmaceutical composition
- alkali metal
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 8
- 230000000087 stabilizing Effects 0.000 title claims 2
- 150000007524 organic acids Chemical class 0.000 claims 13
- 101700042506 HIRUD Proteins 0.000 claims 12
- 229940006607 Hirudin Drugs 0.000 claims 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 6
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 150000001735 carboxylic acids Chemical class 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 238000004108 freeze drying Methods 0.000 claims 3
- 239000004135 Bone phosphate Substances 0.000 claims 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- -1 tribasic carboxylic acids Chemical class 0.000 claims 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
Claims (14)
или в β-перегруппированный фрагмент, представленный общей формулой (2),
способом, включающим в себя: получение раствора указанного пептида, добавление органической кислоты, добавление гидроксида щелочного металла для доведения pH полученного раствора до 5,0-6,5, и лиофилизацию данного раствора, который по существу состоит из компонентов, происходящих из гидроксида щелочного металла, добавленного для доведения pH, углеводов, таких как белый сахар и маннит, которые включены дополнительно, органической кислоты и данного пептида.1. A method for stabilizing a peptide that contains an —Asp-Gly- or —Asn-Gly- sequence, which, over time, can be converted into a succinimide moiety, represented by the following general formula (1),
or in a β-rearranged fragment represented by the general formula (2),
in a manner that includes: obtaining a solution of the indicated peptide, adding an organic acid, adding an alkali metal hydroxide to bring the pH of the resulting solution to 5.0-6.5, and freeze-drying this solution, which essentially consists of components derived from an alkali metal hydroxide added to bring the pH, carbohydrates, such as white sugar and mannitol, which are optionally included, organic acid and this peptide.
(1)
или в β-перегруппированный фрагмент, представленный общей формулой (2),
и органическую кислоту, с добавлением гидроксида щелочного металла, для доведения pH раствора до 5,0-6,5, и лиофилизация данного раствора, который, по существу, состоит из компонентов, происходящих из гидроксида щелочного металла, добавленного для доведения определенного pH, углеводов, таких как белый сахар и маннит, которые включены дополнительно, органической кислоты и данного пептида, причем молярное соотношение пептида и органической кислоты составляет 1:5-100.8. A lyophilized pharmaceutical composition comprising a peptide that contains the sequence —Asp-Gly— or —Asn-Gly—, which over time can be converted into a succinimide moiety, represented by the following general formula (1),
(one)
or in a β-rearranged fragment represented by the general formula (2),
and organic acid, with the addition of an alkali metal hydroxide, to bring the pH of the solution to 5.0-6.5, and lyophilization of this solution, which essentially consists of components derived from the alkali metal hydroxide added to bring a certain pH, carbohydrates such as white sugar and mannitol, which are optionally included, of an organic acid and a given peptide, the molar ratio of peptide and organic acid being 1: 5-100.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/20957 | 1997-01-20 | ||
JP2095797 | 1997-01-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99118176A true RU99118176A (en) | 2001-06-20 |
RU2180218C2 RU2180218C2 (en) | 2002-03-10 |
Family
ID=12041671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99118176/14A RU2180218C2 (en) | 1997-01-20 | 1998-01-19 | Method of stabilization of hirudine and/or hirudine variants, lyophilized pharmaceutical composition prepared by this method |
Country Status (9)
Country | Link |
---|---|
US (1) | US6274553B1 (en) |
EP (1) | EP0998942A4 (en) |
KR (1) | KR20000070338A (en) |
CA (1) | CA2278199A1 (en) |
NO (1) | NO993533L (en) |
NZ (1) | NZ336793A (en) |
RU (1) | RU2180218C2 (en) |
WO (1) | WO1998031386A1 (en) |
ZA (1) | ZA98438B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60224284T2 (en) | 2001-06-28 | 2008-12-18 | Novo Nordisk A/S | STABLE FORMULATION OF MODIFIED GLP-1 |
WO2004105790A1 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
CN102940879B (en) * | 2003-06-03 | 2017-06-06 | 诺沃挪第克公司 | Stabilized pharmaceutical peptide compositions |
CN104826116A (en) * | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
EP1722819B1 (en) * | 2004-03-12 | 2007-12-26 | Intercell AG | Method for solubilising peptide mixtures |
ES2442223T3 (en) | 2004-08-31 | 2014-02-10 | Novo Nordisk A/S | Use of tris (hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
CN106137952B (en) | 2004-11-12 | 2020-11-17 | 诺和诺德公司 | Stable formulations of insulinotropic peptides |
US8858927B2 (en) * | 2007-12-21 | 2014-10-14 | Lyotropic Therapeutics, Inc. | Method for protection of peptides or proteins against non-enzymatic deamidation |
JP5406049B2 (en) * | 2008-02-05 | 2014-02-05 | 協和発酵バイオ株式会社 | Method for improving storage stability of glutathione |
US7598343B1 (en) | 2008-07-27 | 2009-10-06 | The Medicines Company | Pharmaceutical formulations of bivalirudin and processes of making the same |
US7582727B1 (en) | 2008-07-27 | 2009-09-01 | The Medicinces Company | Pharmaceutical formulations of bivalirudin and processes of making the same |
US7803762B1 (en) | 2009-08-20 | 2010-09-28 | The Medicines Company | Ready-to-use bivalirudin compositions |
US7985733B1 (en) | 2010-01-06 | 2011-07-26 | The Medicines Company | Buffer-based method for preparing bivalirudin drug product |
TWI762706B (en) | 2017-08-24 | 2022-05-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1 compositions and uses thereof |
US20200368311A1 (en) | 2019-05-20 | 2020-11-26 | MAIA Pharmaceuticals, Inc. | Ready-to-use bivalirudin compositions |
WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3019612A1 (en) | 1980-05-22 | 1981-11-26 | Boehringer Mannheim Gmbh, 6800 Mannheim | STABILIZED THROMBINE PREPARATION |
DE3342139A1 (en) * | 1983-11-22 | 1985-05-30 | Ciba-Geigy Ag, Basel | DESULFATOHIRUDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS |
US5059587A (en) * | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
GB8817160D0 (en) | 1988-07-19 | 1988-08-24 | Ciba Geigy Ag | Novel proteins |
US5164304A (en) | 1989-05-04 | 1992-11-17 | Sri International | Method and vectors for stabilizing hirudin and human laminin b1 expression |
CA2035917C (en) | 1990-02-13 | 2001-10-02 | John L. Krstenansky | Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin |
IL101062A0 (en) | 1991-02-28 | 1992-11-15 | Erba Carlo Spa | Anti-thrombin polypeptides and their preparation |
AU659432B2 (en) * | 1991-03-08 | 1995-05-18 | Novartis Ag | A method for the inhibition or prevention of tumor cell metastasis with hirudin |
US5278289A (en) | 1991-11-12 | 1994-01-11 | Johnson Alan J | Antihemophilic factor stabilization |
DE4140381A1 (en) * | 1991-12-07 | 1993-06-09 | Hoechst Ag, 6230 Frankfurt, De | NEW SYNTHETIC ISOHIRUDINE WITH IMPROVED STABILITY |
US5747447A (en) | 1992-04-30 | 1998-05-05 | Cor Therapeutics | Stable polypeptide composition |
AU679913B2 (en) * | 1992-04-30 | 1997-07-17 | Millennium Pharmaceuticals, Inc. | Stable polypeptide composition |
US5409725A (en) | 1992-06-23 | 1995-04-25 | Philip Connolly | Methods for stabilizing proteins in an acid pH environment and related compositions |
GB9303275D0 (en) * | 1993-02-18 | 1993-04-07 | Ciba Geigy Ag | Pharmaceutical compositions |
GB9401448D0 (en) * | 1994-01-26 | 1994-03-23 | Ciba Geigy Ag | Stable dry powders |
US6165981A (en) * | 1995-03-07 | 2000-12-26 | Dade Behring Inc. | Stabilizing solutions for proteins and peptides |
DE19607239A1 (en) * | 1996-02-27 | 1997-08-28 | Behringwerke Ag | Pharmaceutical composition containing hirudin and process for its preparation |
-
1998
- 1998-01-19 NZ NZ336793A patent/NZ336793A/en unknown
- 1998-01-19 EP EP98900424A patent/EP0998942A4/en not_active Withdrawn
- 1998-01-19 KR KR1019997006569A patent/KR20000070338A/en not_active Application Discontinuation
- 1998-01-19 RU RU99118176/14A patent/RU2180218C2/en active
- 1998-01-19 WO PCT/JP1998/000178 patent/WO1998031386A1/en not_active Application Discontinuation
- 1998-01-19 US US09/341,926 patent/US6274553B1/en not_active Expired - Fee Related
- 1998-01-19 CA CA002278199A patent/CA2278199A1/en not_active Abandoned
- 1998-01-20 ZA ZA98438A patent/ZA98438B/en unknown
-
1999
- 1999-07-19 NO NO993533A patent/NO993533L/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99118176A (en) | METHOD FOR STABILIZING PEPTIDE AND CONTAINING PEPTIDE LYOPHYLIZED PHARMACEUTICAL COMPOSITION OBTAINED BY USING THIS METHOD | |
CA2102693A1 (en) | Protein formulation comprising growth hormone | |
RU92016283A (en) | DERIVATIVES AND ANALOGUES OF 2-DEOXY-2,3-DIDEHYDRO-N-ACETYLNEURAMINIC ACID, METHOD OF THEIR RECEIVING, THEIR USE AS ANTI-VIRUS AGENTS, PHARMACEUTICAL COMPOSITION INSULATION. | |
EA200200220A1 (en) | AIMING MULTIMERAL VISUALIZING AGENTS WITH A MULTI-CUSCLE BINDING MECHANISM | |
DE68903846D1 (en) | NEW GALENIC FORM OF FENOFIBRATE. | |
BG106280A (en) | Pharmacetical compositions containing fenofibrate and preparation method | |
BG102714A (en) | Pharmaceutical composition for immunomodulation based on peptides and adjuvants | |
AU2196592A (en) | Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits | |
FI973363A0 (en) | Nucleic acid composition, its preparation and use | |
RU2001108569A (en) | STABILIZED PHARMACEUTICAL COMPOSITION IN LYOPHILIZED FORM | |
CA2116066A1 (en) | Stabilized composition of troponin for immunoassays and process for stabilizing troponin for immunoassays | |
KR880013572A (en) | Mixed crystals of insulin and insulin derivatives, preparation methods thereof, medicaments containing the same and uses thereof | |
RU2180218C2 (en) | Method of stabilization of hirudine and/or hirudine variants, lyophilized pharmaceutical composition prepared by this method | |
CA2335551A1 (en) | Thyroid hormone analogues and methods for their preparation | |
EP0716613A4 (en) | TREATMENT OF -i(H. PYLORI) ASSOCIATED GASTRODUODENAL DISEASE | |
FR2408352A1 (en) | POULTRY CHOLERA VACCINE | |
KR890006644A (en) | Crystalline β-lactam Hydrate | |
DE69735583D1 (en) | SEMISYNTHETIC PROCESS FOR THE PREPARATION OF DIDEMNINANALOGES | |
SE8803583D0 (en) | PHARMACEUTICAL COMPOSITION | |
EP1439214A3 (en) | Fluorescent group-containing carbodiimide compound and process for producing the compound | |
RU2000116647A (en) | ONE-DOSE SYRINGE CONTAINING A COMPOSITION OF LYOPHYLIZED PROTEIN FOR INJECTION OF VOLUME LESS THAN THAN 0.5 ML | |
RU2001113281A (en) | HIGH PURITY COMPOSITION CONTAINING (7α, 17α) -17-HYDROXY-7-METHYL-19-NOR-17-PREGN-5 (10) -EN-20-IN-3-OH | |
CA2244389A1 (en) | Cilansetron pharmaceutical preparation stabilized against racemization | |
JPS6416799A (en) | H-pth (1-34) composition and its preparation | |
CH611804A5 (en) | Ski brake |